Solid-Phase Parallel Synthesis of 5-Amino- and 5-Amido-1,2,4-thiadiazole Derivatives via Cyclization Reactions of a Carboxamidine Thiourea Linker

Abstract

A general method is described for the solid-phase parallel synthesis of 5-amino- and 5-amido-1,2,4-thiadiazoles. The sequence developed for this purpose is based on cyclization reactions of resin-bound carboxamidine thioureas promoted by p-toluenesulfonyl chloride. The resin-bound carboxamidine thioureas, produced by addition of arylcarboxamidines to a isothiocyanate terminated resin, serve as key intermediates that undergo cyclizations to generate 5-amino-1,2,4-thiadiazole resins. N-Alkylation or N-acylation reactions of 5-amino-1,2,4-thiadiazole resins yield the desired variously functionalized 1,2,4-thiadiazole resins. Finally, 5-amino- and 5-amido-1,2,4-thiadiazoles are then generated in good yields and purities by cleavage of the respective 1,2,4-thiadiazole resins under TFA in CH₂Cl₂.

solid-phase parallel synthesis - 5-substituted 1,2,4-thiadiazole - thiourea carboxamidine linker

References and Notes

1a Krchňák V. Holladay MW. Chem. Rev.  2002,  102:  61 

1b Thompson LA. Ellman JA. Chem. Rev.  1996,  96:  555 

1c Terrett NK. Gardner M. Gordon DW. Kobylecki RJ. Steele J. Tetrahedron  1995,  51:  8135 

2a Kumar H. Javed SA. Khan SA. Amir M. Eur. J. Med. Chem.  2008,  43:  2688 

2b Shen L. Zhang Y. Wang A. Sieber-McMaster E. Chen X. Pelton P. Xu JZ. Yang M. Zhu P. Zhou L. Reuman M. Hu Z. Russell R. Gibbs AC. Ross H. Demarest K. Murray WV. Kuo G.-H. Bioorg. Med. Chem.  2008,  16:  3321 

2c Castro A. Castaño T. Encinas A. Porcal W. Gil C. Bioorg. Med. Chem.  2006,  14:  1644 

2d Teng X. Keys H. Jeevanandam A. Porco JA. Degterev A. Yuan J. Cuny GD. Bioorg. Med. Chem. Lett.  2007,  17:  6836 

3a Mullican MD. Wilson MW. Connor DT. Kostlan CR. Schrier DJ. Dyer RD. J. Med. Chem.  1993,  36:  1090 

3b Song Y. Connor DT. Sercel AD. Sorenson RJ. Doubleday R. Unangst PC. Roth BD. Beylin VG. Beylin VG. Gilbertsen RB. Chan K. Schrier DJ. Guglietta A. Bornemeier DA. Dyer RD. J. Med. Chem.  1999,  42:  1161 

3c Labanauskas L. Kalcas V. UdrenaiteE . Gaidelis P. Brukstus A. Dauksas A. Pharmazie  2001,  56:  617 

3d Boschelli DH. Connor DT. Bornemeier DA. Dyer RD. Kennedy JA. Kuipers PJ. Okonkwo GC. Schrier DJ. Wright CD. J. Med. Chem.  1993,  36:  1802 

4a El-Emam AA. Al-Deeb OA. Al-Omar M. Lehmann J. Bioorg. Med. Chem.  2004,  12:  5107 

4b Dogan HN. Duran A. Rollas S. Sener G. Uysal MK. Gülen D. Bioorg. Med. Chem.  2002,  10:  2893 

4c Hollar BS. Gonsalves R. Shenoy S. Eur. J. Med. Chem.  2000,  35:  267 

5a Chapleo CB. Myers M. Myers PL. Saville JF. Smith ACB. Stillings MR. Tulloch IF. Walter DS. Welbourn AP. J. Med. Chem.  1986,  29:  2273 

5b Chapleo CB. Myers PL. Smith AC. Stillings MR. Tulloch IF. Walter DS. J. Med. Chem.  1988,  31:  7 

5c Akbarzadeh T. Tabatabai SA. Khoshnoud MJ. Shafaghi D. Shafiee A. Bioorg. Med. Chem.  2003,  11:  769 

5d Foroumadi A. Tabatabai SA. Gitinezhad G. Zarrindast MR. Shafiee A. Pharm. Pharmacol. Commun.  2000,  6:  1 

6a Turner S. Myers M. Gadie B. Nelson AJ. Pape R. Saville JF. Doxey JC. Berridge TL. J. Med. Chem.  1988,  31:  902 

6b Turner S. Myers M. Gadie B. Hale SA. Horsley A. Nelson AJ. Pape R. Saville JF. Doxey JC. Berridge TL. J. Med. Chem.  1988,  31:  907 

6c Tyagi M. Kumar A. Oriental J. Chem.  2002,  18:  125 

7a Yoo S.-e. Seo J.-s. Yi KY. Gong Y.-D. Tetrahedron Lett.  1997,  38:  1203 

7b Yoo S.-e. Gong Y.-D. Seo J.-s. Sung M.-M. Lee S. Kim Y. J. Comb. Chem.  1999,  1:  177 

7c Gong Y.-D. Yoo S.-e. Bull. Korean Chem. Soc.  2001,  21:  941 

7d Gong Y.-D. Seo J.-s. Chon Y.-S. Hwang J.-Y. Park J.-Y. Yoo S.-e. J. Comb. Chem.  2003,  5:  577 

7e Lee IY. Kim SY. Lee JY. Yu C.-M. Lee DH. Gong Y.-D. Tetrahedron Lett.  2004,  45:  9319 

8a Fawzi AB. Macdonald D. Bendow LL. Smith Torhan A. Zhang HT. Weig BC. Ho G. Tulshian D. Linder ME. Graziano MP. Mol. Pharmacol.  2001,  59:  30 

8b Lanzafame A. Christopoulos A. J. Pharmacol. Exp. Ther.  2004,  308:  830 

8c Castro A. Castano T. Encinas A. Porcal W. Gil C. Bioorg. Med. Chem.  2006,  14:  1644 

9 Park JY. Ryu IA. Park JH. Ha DC. Gong Y.-D. Synthesis  2009,  in press

10

General Procedure for the Synthesis of 5-Amino-substituted 1,2,4-Thiadiazoles (8a)
Preparation of Isothiocyanate-Terminated Resin 2 To a mixture of BOMBA resin 1 (5.00 g, 6.0 mmol) in CH₂Cl₂ (120 mL) was added Et₃N (3.35 mL, 24.0 mmol) and CSCl₂ (1.84 mL, 24.0 mmol) at 0 ˚C. The mixture was stirred at r.t. for 5 h. The precipitate obtained by filtration of the mixture was washed with CH₂Cl₂ and MeOH and dried in a vacuum oven. This process gave resin 2 (5.24 g) as a dark brown solid. Single-bead ATR-FTIR: 2071 (N=C=S), 1610, 1590, 1507, 1493, 1451, 1421, 1376, 1286, 1266, 1196, 1160, 1114, 1029, 1017, 943, 819, 757, 697 cm^-¹.
Preparation of Carboxamidine Thiourea Resin 4a
A mixture of isothiocyanate resin 2 (5.00 g, 5.71 mmol), benzamidine hydrochloride (2.68 g, 17.1 mmol), and DBU (5.12 mL, 34.3 mmol) in DCE (120 mL) was stirred at 60 ˚C 16 h. The resin was filtered and washed several times with CH₂Cl₂ and MeOH and dried in a vacuum oven. Resin 4a was obtained as a light brown solid (5.62 g). Single-bead ATR-FTIR: 1611, 1505, 1492, 1448, 1375, 1284, 1195, 1158, 1113, 1029, 820, 756, 697 cm^-¹. Preparation of 5-Amino-3-phenyl-1,2,4-thiadiazole Resin 5a A mixture of carboxamidine thiourea resin 4a (5.00 g, 5.02 mmol), Et₃N (2.10 mL, 15.1 mmol), and p-TsCl (2.87 g, 15.1 mmol) in DCE (120 mL) was stirred at 60 ˚C for 8 h. Filtration gave a precipitate, which was washed several times with CH₂Cl₂ and MeOH and dried in a vacuum oven. Resin 5a was obtained as a light brown solid (4.87 g). Single-bead ATR-FTIR: 1614, 1558, 1506, 1493, 1451, 1421, 1346, 1286, 1195, 1158, 1118, 1029, 816, 757, 697 cm^-¹. Preparation of 5-Benzylamino-3-phenyl-1,2,4-thiadi-azole Resin 6a To a mixture of 5-amino-1,2,4-thiadiazole resin 5a (200 mg, 0.20 mmol) in DMF (5 mL) was added NaH (24.0 mg, 0.6 mmol, 60% dispersion in mineral oil) at r.t. The resulting mixture was stirred for 10 min. Benzyl chloride (115.1 µL, 1.0 mmol) was added, and the resulting mixture was stirred at 60 ˚C for 24 h. The resin was filtered and washed several times with DMF, H₂O, MeOH, and CH₂Cl₂, and then the resin was dried in a vacuum oven. Resin 6a was obtained as a brown solid (203 mg). Single-bead ATR-FTIR: 1606, 1587, 1544, 1505, 1493, 1451, 1340, 1286, 1264, 1196, 1159, 1114, 1028, 820, 758, 733, 697 cm^-¹. Preparation of 5-Benzamide-3-phenyl-1,2,4-thiadiazole Resin 7a
To a mixture of the 5-amino-1,2,4-thiadiazole resin 5a (200 mg, 0.20 mmol) in THF (5 mL) was sequentially added LiHMDS (1.0 mL, 1.0 mmol, 1.0 M solution in hexanes), benzoyl chloride (116.1 µL, 1.0 mmol), and DMAP (12.2 mg, 0.1 mmol) at r.t. The mixture was stirred at 60 ˚C for 24 h. The resin was filtered and washed several times with DMF, H₂O, MeOH, and CH₂Cl₂ and then dried in a vacuum oven. Resin 7a was obtained as a brown solid (206 mg). Single-bead ATR-FTIR: 1653 (NC=O), 1602, 1586, 1504, 1491, 1449, 1376, 1284, 1263, 1195, 1158, 1112, 1026, 1017, 819, 757, 733, 696 cm^-¹. Preparation of N -Benzyl-3-phenyl-1,2,4-thiadiazol-5-amine 8a from Resin 6a A mixture of 5-benzylamino-3-phenyl-1,2,4-thiadiazole resin 6a (203 mg, 0.20 mmol) and 3 mL of cleavage cocktail (TFA-CH₂Cl₂ = 1:4, v/v) was shaken at r.t. for 4 h. The resin was filtered and the filtrate was concentrated in vacuo giving a residue which was dissolved in CH₂Cl₂. The solution was eluted through a SAX cartridge (CH₂Cl₂). The eluent was concentrated in vacuo giving a residue which was subjected to SiO₂ column chromatography (n-hexane-EtOAc, 8:1) to afford 8a (15.3 mg, 28%; 90% purity). ^¹H NMR (500 MHz, CDCl₃): δ = 8.17-8.14 (m, 2 H), 7.43-7.39 (m, 3 H), 7.38-7.31 (m, 5 H), 6.47 (s, 1 H), 4.52 (d, 2 H, J = 5.6 Hz). ^¹³C NMR (125 MHz, CDCl₃): δ = 50.6, 127.8, 128.1, 128.4, 128.6, 129.1, 130.1, 133.4, 136.3, 170.0, 184.6 cm^-¹. LC-MS (ESI): m/z = 268 [M + 1]⁺. HRMS (EI): m/z [M]⁺ calcd for C₁₅H₁₃N₃S₁: 267.0830; found: 267.0829. Synthesis of N -(3-Phenyl-1,2,4-thiadiazol-5-yl)benz-amide 9a from Resin 7a A mixture of 3-phenyl-5-benzamide-1,2,4-thiadiazole resin 7a (206 mg, 0.20 mmol) and the cleavage cocktail (3 mL; TFA-CH₂Cl₂ = 1:4) was shaken at r.t. for 4 h. Filtration followed by washing the precipitate with CH₂Cl₂ gave a filtrate which was concentrated in vacuo to give a residue that was eluted through a SAX cartridge (CH₂Cl₂). The eluent was concentrated in vacuo to give a residue was subjected to SiO₂ column chromatography (n-hexane-EtOAc, 8:1) to afford 9a (14.6 mg, 26%; 99% purity). ^¹H NMR (500 MHz, CDCl₃): δ = 10.71 (s, 1 H), 8.19-8.14 (m, 2 H), 7.93-7.90 (m, 2 H), 7.60-7.56 (m, 1 H), 7.47-7.43 (m, 2 H), 7.42-7.38 (m, 3 H). ^¹³C NMR (125 MHz, CDCl₃): δ = 127.8, 127.9, 128.8, 129.3, 130.4, 130.6, 132.8, 133.8, 165.8, 167.9, 175.8. LC-MS (ESI): m/z = 282 [M + 1]⁺. HRMS (EI): m/z [M]⁺ calcd for C₁₅H₁₁N₃O₁S₁: 281.0623; found: 281.0616.